Hims & Hers Health, Inc. (NYSE:HIMS) Stock Holdings Increased by Amundi

Amundi boosted its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 49.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,741 shares of the company’s stock after buying an additional 4,197 shares during the quarter. Amundi’s holdings in Hims & Hers Health were worth $328,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quest Partners LLC grew its holdings in shares of Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after purchasing an additional 807 shares during the last quarter. Stonekeep Investments LLC lifted its position in Hims & Hers Health by 5.5% in the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock worth $410,000 after purchasing an additional 882 shares during the period. Principal Securities Inc. lifted its position in Hims & Hers Health by 48.2% in the fourth quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock worth $74,000 after purchasing an additional 1,002 shares during the period. Victory Capital Management Inc. increased its holdings in shares of Hims & Hers Health by 1.9% in the fourth quarter. Victory Capital Management Inc. now owns 52,579 shares of the company’s stock valued at $1,271,000 after buying an additional 1,002 shares in the last quarter. Finally, Cadent Capital Advisors LLC increased its holdings in shares of Hims & Hers Health by 1.5% in the fourth quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company’s stock valued at $1,745,000 after buying an additional 1,060 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Soleil Boughton sold 268,932 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the sale, the insider now directly owns 169,803 shares of the company’s stock, valued at $4,712,033.25. This represents a 61.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Oluyemi Okupe sold 4,213 shares of the stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $29.98, for a total transaction of $126,305.74. Following the sale, the chief financial officer now directly owns 128,365 shares in the company, valued at $3,848,382.70. This trade represents a 3.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,015,547 shares of company stock valued at $36,146,450 over the last three months. 17.71% of the stock is owned by insiders.

Hims & Hers Health Trading Up 5.8 %

NYSE HIMS opened at $34.77 on Friday. The firm has a market cap of $7.72 billion, a price-to-earnings ratio of 79.02 and a beta of 1.37. The company has a 50 day moving average of $39.21 and a 200-day moving average of $28.69. Hims & Hers Health, Inc. has a 1-year low of $11.20 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

HIMS has been the topic of a number of research reports. Bank of America upped their price target on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a research note on Tuesday. Piper Sandler upped their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, February 25th. Citigroup restated a “sell” rating and set a $27.00 price target on shares of Hims & Hers Health in a report on Thursday, March 6th. BTIG Research started coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price for the company. Finally, Morgan Stanley cut shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their target price for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $37.31.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.